Cargando…

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

BACKGROUND: Three quarter of endometrial carcinomas are treated at early stage. Still, 15 to 20% of these patients experience recurrence, with little effect from systemic therapies. Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue (KRAS) mutations have been reported to have an im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birkeland, E, Wik, E, Mjøs, S, Hoivik, E A, Trovik, J, Werner, H M J, Kusonmano, K, Petersen, K, Raeder, M B, Holst, F, Øyan, A M, Kalland, K-H, Akslen, L A, Simon, R, Krakstad, C, Salvesen, H B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Genetics & Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516681/ https://www.ncbi.nlm.nih.gov/pubmed/23099803 http://dx.doi.org/10.1038/bjc.2012.477

Ejemplares similares

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer
por: Stefansson, Ingunn M., et al.
Publicado: (2015)

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer
por: Mauland, K K, et al.
Publicado: (2011)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

Lipocalin 2 expression is associated with aggressive features of endometrial cancer
por: Mannelqvist, Monica, et al.
Publicado: (2012)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer
por: Mjos, Siv, et al.
Publicado: (2017)

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
por: Krakstad, Camilla, et al.
Publicado: (2015)

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
por: Hoivik, Erling A., et al.
Publicado: (2014)

Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
por: Raeder, Maria B., et al.
Publicado: (2013)

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses
por: Bredholt, Geir, et al.
Publicado: (2015)

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
por: Mauland, Karen Klepsland, et al.
Publicado: (2016)

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer
por: Kusonmano, Kanthida, et al.
Publicado: (2018)

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients
por: Berg, Anna, et al.
Publicado: (2014)

Switch in FOXA1 Status Associates with Endometrial Cancer Progression
por: Tangen, Ingvild Løberg, et al.
Publicado: (2014)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma
por: Engelsen, I B, et al.
Publicado: (2008)

Androgen receptor as potential therapeutic target in metastatic endometrial cancer
por: Tangen, Ingvild Løberg, et al.
Publicado: (2016)

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
por: Holst, Frederik, et al.
Publicado: (2016)

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
por: Holst, Frederik, et al.
Publicado: (2016)

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
por: Holst, Frederik, et al.
Publicado: (2017)

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers
por: Berg, Anna, et al.
Publicado: (2017)

An 18-Gene Signature for Vascular Invasion Is Associated with Aggressive Features and Reduced Survival in Breast Cancer
por: Mannelqvist, Monica, et al.
Publicado: (2014)

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
por: Engerud, Hilde, et al.
Publicado: (2019)

Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease
por: Lien, Hilde E., et al.
Publicado: (2023)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
por: Karlsson, Thomas, et al.
Publicado: (2016)

Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups
por: Askeland, Cecilie, et al.
Publicado: (2020)

High visceral fat percentage is associated with poor outcome in endometrial cancer
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer
por: Jacob, Havjin, et al.
Publicado: (2021)

A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer
por: Ingebriktsen, L. M., et al.
Publicado: (2022)

Independent prognostic importance of microvessel density in endometrial carcinoma.
por: Salvesen, H. B., et al.
Publicado: (1998)

Whole‐Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
por: Gibson, William J., et al.
Publicado: (2016)

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer
por: Berg, Anna, et al.
Publicado: (2016)

PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis
por: Bredin, Hanna K., et al.
Publicado: (2023)

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas
por: Haldorsen, I S, et al.
Publicado: (2014)

Amplification of the 20q Chromosomal Arm Occurs Early in Tumorigenic Transformation and May Initiate Cancer
por: Tabach, Yuval, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4ivotktenseo8nm74psvcmqjea